Get started
Author

Teja Turpuseema

ORCID: 0000-0001-8056-0152
Observed ORCID: 0000-0001-8056-0152
OpenAlex ID: A5048388672
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
2022 · Lindsey E. Roeker, Tatyana A. Feldman, et al. · Clinical Cancer Research · 14
PDF
Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
2023 · Lindsey E. Roeker, Tatyana A. Feldman, et al.
Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
2023 · Lindsey E. Roeker, Tatyana A. Feldman, et al.
Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
2023 · Lindsey E. Roeker, Tatyana A. Feldman, et al.
Abstract 5790: TG-1601 is a novel BET inhibitor with strong binding affinity and long-lasting effect in pre-clinical models
2018 · Emmanuel Normant, Leonid Gorelik, et al. · Cancer Research
Works count: 5
Citation count: 14
H-index: 1
I10-index: 1
Year
Topic
Type